The absence of HIV mutations in cerebrospinal fluid and in peripheral blood mononuclear cells during a regimen containing Trizivir plus tenofovir.
d'Ettorre
G
G
Department of Tropical and Infectious Diseases, University of Rome Sapienza, Rome, Italy. gabriella.dettorre@uniroma1.it
Ceccarelli
G
G
Turriziani
O
O
Andreotti
M
M
Massetti
P
P
Rizza
C
C
Vella
S
S
Antonelli
G
G
Mastroianni
C M
CM
Vullo
V
V
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D009154:Mutation / Q000235:genetics*; D063065:Organophosphonates / Q000627:therapeutic use*; D011446:Prospective Studies; D000068698:Tenofovir; D014766:Viremia / Q000097:blood* / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D015215:Zidovudine / Q000627:therapeutic use*; D000099227:Abacavir
D000225:Adenine; D019380:Anti-HIV Agents; D004338:Drug Combinations; D019259:Lamivudine; D063065:Organophosphonates; D000068698:Tenofovir; D015215:Zidovudine; C418262:abacavir, lamivudine, and zidovudine drug combination; D000099227:Abacavir